VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today announced that its founder, President and Chairman of the Board, Maximilian de Clara has resigned for personal health reasons, effective immediately. The 87 year-old visionary funded the original research of what has become CEL-SCI’s investigational drug Multikine* at the Max Planck Institute in Germany. From this he started the Company and now the Multikine Phase 3 study is being run in 24 countries with multiple respected partners. We thank him for his dedication and service to the Company, and wish him the best of health.
"Mr. de Clara believed in the concept of immunotherapy for cancer patients when very few did. He believed that the immune system holds the key to the treatment of many diseases. He also believed that the immune system should be activated before radiation and chemotherapy when it is thought to be strongest. Without Mr. de Clara’s determination backed by his personal funds CEL-SCI would not exist today.” said CEL-SCI CEO Geert Kersten.
Mr. Maximilian de Clara said: “It is with sadness that I acknowledge that I can no longer handle the operational obligations of the Company I have built, financed and nurtured for the last thirty three years. While I will no longer actively participate in the daily operation of CEL-SCI, I have the utmost confidence in the management team in place and in the continued success of Multikine’s clinical progress.”
CEL-SCI does not plan to fill the position of President at this time.
About CEL-SCI Corporation
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the head and neck. If the study endpoint, which is an improvement in overall survival of the subjects treated with the Multikine treatment regimen plus the current standard of care (SOC) as compared to subjects treated with the current SOC only, is satisfied, the study results will be used to support applications that the Company plans to submit to regulatory agencies in order to seek commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase 1 trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase 1 trial at UCSF. CEL-SCI has issued patents on Multikine from the US, Europe, China and Japan.
